Skip to contentI
Integra Lifesciences Holdings Corp
I
IARTIntegra Lifesciences Holdings Corp Q3 2025 · 10-Q
Revenue$402.06M$402.06M+5.6% vs Q3 2024 Net Income-$5.40M-$5.40MN/M vs Q3 2024 EPS Diluted-$0.07-$0.07N/M vs Q3 2024 Operating Income$11,761,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Integra Lifesciences Holdings Corp · CIK 917520 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$25,750,000N/M Margins · derivedOperating margin2.9%+5.1 pt vs Q3 2024
Net margin-1.3%+1.5 pt vs Q3 2024
ended Sep 30, 2025 · filed Oct 30, 2025 · 30 d after period end